DS
ORIC icon

David Shaw’s Oric Pharmaceuticals ORIC Stock Holding History

David Shaw’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Buy
1,580,216
+1,535,826
+3,460% +$13.9M 0.01% 1405
2026
Q1 		$562K Buy
44,390
+28,368
+177% +$322K ﹤0.01% 3788
2025
Q4 		$131K Buy
+16,022
New +$184K ﹤0.01% 4381
2024
Q1 		– Sell
-98,433
Closed -$906K – 4623
2023
Q4 		$906K Sell
98,433
-209,046
-68% -$1.51M ﹤0.01% 3200
2023
Q3 		$1.86M Sell
307,479
-145,770
-32% -$1.19M ﹤0.01% 2631
2023
Q2 		$3.52M Sell
453,249
-125,054
-22% -$710K ﹤0.01% 2146
2023
Q1 		$3.3M Sell
578,303
-24,484
-4% -$128K ﹤0.01% 2304
2022
Q4 		$3.55M Buy
602,787
+68,899
+13% +$233K ﹤0.01% 2412
2022
Q3 		$1.71M Buy
533,888
+27,901
+6% +$112K ﹤0.01% 3137
2022
Q2 		$2.27M Buy
505,987
+261,088
+107% +$1.04M ﹤0.01% 2957
2022
Q1 		$1.31M Buy
+244,899
New +$2.21M ﹤0.01% 3689
2021
Q2 		– Sell
-9,812
Closed -$240K – 4942
2021
Q1 		$240K Buy
+9,812
New +$310K ﹤0.01% 3790

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's ORIC Position: Q2 2026 in Review

David Shaw increased its Oric Pharmaceuticals (ORIC) stake by 3,460% in Q2 2026, buying an estimated $13.9M and bringing the position to 1,580,216 shares worth $17.1M. The position accounts for 0.01% of the portfolio, ranked #1405.

David Shaw first reported a position in ORIC in Q1 2021 and has held it in 12 quarters since. 179 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • David Shaw held 1,580,216 shares of Oric Pharmaceuticals worth $17.1M as of Q2 2026.
  • David Shaw bought 1,535,826 Oric Pharmaceuticals shares in Q2 2026, an estimated $13.9M.
  • Oric Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1405 holding.
  • David Shaw first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
  • 179 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.